Arena Pharma (ARNA) Tops Q1 EPS by 1c
Get Alerts ARNA Hot Sheet
Price: $99.98 --0%
Financial Fact:
Total interest and other expense, net: -2.62M
Today's EPS Names:
NLY, CP, RUSHA, More
Financial Fact:
Total interest and other expense, net: -2.62M
Today's EPS Names:
NLY, CP, RUSHA, More
Join SI Premium – FREE
Arena Pharma (NASDAQ: ARNA) reported Q1 EPS of ($0.09), $0.01 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $9.02 million.
BELVIQ® (lorcaserin HCl) Update
- IMS Health estimates that approximately 121,000 prescriptions for BELVIQ were filled in the United States in the first quarter of 2016.
- Ildong Pharmaceutical Co., Ltd., estimates that approximately 2.1 million tablets of BELVIQ were prescribed in South Korea in the first quarter of 2016, which equates to approximately 34,700 one-month prescriptions.
For earnings history and earnings-related data on Arena Pharma (ARNA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
- Celestica (CLS) Tops Q1 EPS by 14c
- First Bancorp. (FBNC) Misses Q1 EPS by 2c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!